International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). (Q37530452)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 June 2009

Language	Label	Description	Also known as
English	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).	scientific article published on 25 June 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

object named as

R Hajek

14

0 references

Giampaolo Merlini

object named as

G Merlini

11

0 references

Angela Dispenzieri

object named as

A Dispenzieri

9

0 references

Athanasios Dimopoulos

18

object named as

M A Dimopoulos

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

S. Vincent Rajkumar

38

object named as

S V Rajkumar

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Edward A. Stadtmauer

2

object named as

E A Stadtmauer

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

22

object named as

M Gertz

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

20

object named as

B Barlogie

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

39

object named as

B G M Durie

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

author name string

S Giralt

1

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

J L Harousseau

3

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

A Palumbo

4

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

W Bensinger

5

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

R L Comenzo

6

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

S Kumar

7

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

N C Munshi

8

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

R Kyle

10

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

J San Miguel

12

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

H Ludwig

13

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

S Jagannath

15

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

J Blade

16

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

S Lonial

17

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

H Einsele

19

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

K C Anderson

21

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

M Attal

23

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

P Tosi

24

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

P Sonneveld

25

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

M Boccadoro

26

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

G Morgan

27

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

O Sezer

28

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

M V Mateos

29

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

M Cavo

30

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

D Joshua

31

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

I Turesson

32

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

W Chen

33

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

K Shimizu

34

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

R Powles

35

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

P G Richardson

36

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

R Niesvizky

37

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

IMWG

40

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

publication date

25 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1904-1912

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling tr

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Secondary failure of platelet recovery after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

The VAD chemotherapy regimen plus a G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

The Arkansas approach to therapy of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Current status of autologous hematopoietic stem cell transplantation in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors that influence collection and engraftment of autologous peripheral-blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.127

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37530452&oldid=2200502910"